Express Scripts Inc. Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (31)

Latest Posts

About This Stock More About This Stock
Barclays Sees Upside For Cigna Even With No Deal As Icahn Opposes Merger
Article By: The Fly
Tuesday, August 7, 2018 12:32 PM EDT
If the deal is approved, the analyst sees Cigna shares falling to $180 in the near-term.
In this article: CI, ESRX Also: AMZN, ANTM
Read
Cigna Investor Carl Icahn Plans To Vote Against Express Scripts Deal, WSJ Says
Article By: The Fly
Thursday, August 2, 2018 6:17 AM EDT
According to a WSJ report, activist investor Carl Icahn, who has built a sizable stake in Cigna (CI), is planning to vote against the company's planned $54B acquisition of Express Scripts (ESRX).
In this article: CI, ESRX, AMZN
Read
M&A Hits Record In 1H: Ride High With These ETFs
Article By: Sweta Killa
Saturday, July 21, 2018 5:13 PM EDT
Merger and acquisition activities across the globe hit record highs in the first half of 2018 driven by growing ambition of American companies. We have highlighted three merger ETFs to ride out the surge from the increasing M&A deals.
In this article: CI, T, TWX, ESRX, FOXA, COL, MNA, ANDV, MRGR
Read
E Portfolio Review - June 4, 2018
Article By: Ingrid Hendershot
Monday, June 4, 2018 7:12 AM EDT
Here is a roundup covering the latest news on the stocks in our portfolio. As well as plans to add two more stocks.
In this article: ABBV, ESRX, CI, CAKE, NKE, CNI, THO, FB
Read
A Peek Into Latest 13-F Filing: Top Hedge Fund Stocks
Article By: Sweta Killa
Friday, May 18, 2018 9:08 PM EDT
Investors are mulling over the top bets of big investors like Bill Ackman, George Soros, Carl Icahn, David Tepper, Larry Robbins, Leon Cooperman, Daniel Loeb, David Einhorn and Stanley Druckenmiller, following the first-quarter release of 13F Forms.
In this article: EA, AAPL, ADBE, AMZN, MSFT, NFLX, FB, GOOGL, TWX, UNH, ANTM, CVS, ESRX, GRBK, TUSK, GHDX, ZGNX, RTRX, PCRX, PTCT, CORI, SBBP
Read

PARTNER HEADLINES

Latest Tweets for $ESRX

No tweets yet!